Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 7/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29134465 | 0.87 | L3MBTL1 (0.41) | NR1H2MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL2926879 | 0.83 | NR1H2 (0.40) | NR1H2GABRG2GABRB3GABRA5CHRM2 | |
| SCHEMBL29954668 | 0.83 | NR1H2 (0.40) | NR1H2GABRG2GABRB3GABRA5CHRM2 | |
| SCHEMBL2878161 | 0.83 | NR1H2 (0.40) | NR1H2GABRG2GABRB3GABRA5CHRM2 | |
| SCHEMBL22300959 | 0.82 | GABRG2 (0.32) | NR1H2KMT2AGABRG2GABRB3GABRA5 | |
| SCHEMBL760776 | 0.82 | NR1H2 (0.38) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL599783 | 0.81 | NR1H2 (0.40) | NR1H2GABRG2GABRB3GABRA5CHRM2 | |
| SCHEMBL2873485 | 0.81 | NR1H2 (0.40) | NR1H2GABRG2GABRB3GABRA5CHRM2 | |
| SCHEMBL10214934 | 0.81 | NR1H2 (0.37) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL759123 | 0.81 | NR1H2 (0.40) | NR1H2MAPTCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144850-A1 | INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-05-12 | — | — | US | disclosed |
| EP-3919495-A1 | INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-12-08 | — | — | EP | disclosed |
| WO-2021018298-A1 | INDOLO-SEVEN-MEMBERED ACYLOXIME COMPOUNDS AS PARP INHIBITORS | 南京明德新药研发有限公司 | 2021-02-04 | — | — | WO | disclosed |
| WO-2020156577-A1 | INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR | 正大天晴药业集团股份有限公司 | 2020-08-06 | — | — | WO | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| EP-2001480-A2 | INDAZOLE COMPOUNDS | Abbott Laboratories (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | NR1H2 408/4885CYP11B2 10/4885MEN1 878/4885 |
| US-20220144850-A1 | INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR | PARP1, PARP2, PARP3 | NR1H2 1953/4885CYP11B2 1388/4885MEN1 3060/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | NR1H2 408/4885CYP11B2 10/4885MEN1 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.